



Consultations

Consultation on the draft 2022/23 Invitation to tender (for Healthcare professionals)

21 July 2022

Overview

Te Pātaka Whaioranga – Pharmac is seeking feedback from healthcare professionals, medical groups, hospital pharmacies, and other interested parties on the contents of the 2022/23 Invitation to Tender.

Consultation closes at 5 pm on Thursday 25 August 2022

Email feedback to tender@pharmac.govt.nz

We're particularly interested in feedback on:

- the appropriateness of a brand change for products included in the draft tender list
- any particular usability or suitability requirements that should be considered when evaluating potential products
- whether or not there are any particular clinical situations or patient circumstances for these products that might require delaying or avoiding a brand change
- whether or not there would be any clinical issues or other consequences that should prevent us from either enabling all-at-once dispensing or removing any remaining funding restrictions.

Please contact us if you wish to discuss the proposals contained in this consultation.

We are also seeking feedback from the pharmaceutical industry and people who take medicines.

- [Pharmaceutical industry](#)
- [Patients' and public consultation](#)

Although this consultation has been widely distributed, should you consider that a particular person, group, or agency should receive it and/or future tender documents, please let us know or share it with them directly.

All tender documents and consultations are available from the Pharmac website: [pharmac.govt.nz/consultations-and-decisions](https://www.pharmac.govt.nz/consultations-and-decisions)

About the tender

Pharmac's annual tender is used to contract for supply of medicines that are already funded in New Zealand and are no longer under patent.

The tender helps to secure the ongoing supply of medicines and generates savings that can be used to fund new medicines. Each year, a portion of the medicines on the Schedule is included in the annual tender. This means that, although the tender is run annually, the list of medicines included in it changes from year to year. Typically, each medicine is put out to tender every three years.

Before we run the annual tender, we seek feedback from clinicians, patient advocacy groups, the pharmaceutical industry, and others. This helps ensure that:

- tendering is appropriate for each medicine
- we are alerted to any potential issues when considering a change in brand for a particular product.

We get expert advice on every decision we make from Pharmac's [Tender Clinical Advisory Committee](#). The committee is made up of medical practitioners, nurse practitioners, and pharmacists. We'll also seek further advice from specialists in particular fields, such as oncology, psychiatry, and neurology, as appropriate.

What the tender means

If we award a tender for a medicine to a pharmaceutical supplier, then that supplier's brand becomes the principal brand of that medicine. It would likely be the only brand of that medicine funded in the Schedule (Principal Supply Status) until 30 June 2026.

If that brand was already the only funded brand, there would be no noticeable difference for most people, although the price that Pharmac (or hospitals) pay may change.

If that brand was not currently listed on the Schedule, we would change from the old brand to the new one over time. This involves:

- We would inform the sector of the upcoming change, at least 1 month before any changes occurred.
- Then the new brand would be listed in the Schedule, meaning that both the old and new brands would be available and funded.
- Five months later, the old brand would be removed from the Schedule.

Access to other brands

We expect that most people will start on, or transition to, the new brand easily. However, we know that people's experiences will differ. The alternative brand allowance lets us support people who may experience, or are at heightened risk of, adverse clinical outcomes from a brand change. This may mean either:

- moving back to the old brand after adverse side effects or reduction in efficacy after trialling the new brand
- having a longer period of time in which to change brands

- allowing some patients to avoid switching altogether.

The tender gives Pharmac the flexibility to fund alternative brands in different ways. In hospitals, for example:

- In hospitals, we expect to continue to use the Discretionary Variance provisions in the Schedule. This lets hospitals purchase alternative brands up to a certain percent of volume, typically 5 percent.
- In the community, alternative brands could be funded through:
 - listing (or maintaining the listing of) other brands under strict Special Authority criteria, or
 - managing case-by case approvals through our exceptional circumstances framework.

While Pharmac can fund alternative brands, continued supply of a particular alternative brand cannot always be guaranteed. It is helpful to understand what products might need greater access to alternative brands before we run the tender.

We are keen to understand:

- which medicines, indications, or patient groups might need funding for an alternative brand and, if so, why?
- whether or not you consider that clinical destabilisation can be objectively determined in those circumstances and, if so, how?

Other potential changes

Because the tender can result in substantial price reductions, it often means that savings made can be used to fund new medicines. However, these price reductions can also lead to other changes for the tendered products. For example:

- if the product is currently partially funded (people pay a part-charge in addition to the prescription co-payment), it could become fully funded after the tender
- we may make it easier for people to have their prescriptions filled all at once (rather than in monthly lots) by adding a product to the 'stat' dispensing list
- if funding criteria apply to a product (for example, a Special Authority restriction, endorsement, or prescriber-type restriction), we might change or remove funding restrictions to enable more people to use it.

We are interested in your feedback on the clinical appropriateness of these potential changes. You can see the Pharmaceutical Schedule for all dispensing and funding restrictions: [schedule.pharmac.govt.nz/latest/Schedule.pdf](https://www.pharmac.govt.nz/latest/Schedule.pdf)

The tender list

The list of medicines that we are proposing to include in this year's Invitation to Tender is attached below.

Most of the items in the tender have been included in the annual tender before. However, the following products that have not been tendered previously.

- Cyproterone acetate with ethinyloestradiol – Tab 2 mg with ethinyloestradiol 35 mcg

- Macrogol 3350 with sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid – Powder for oral soln
- Metaraminol tartrate – Inj 0.5 mg per ml, 5 ml
- Metaraminol tartrate – Inj 0.5 mg per ml, 20 ml
- Metaraminol tartrate – Inj 1 mg per ml, 10 ml
- Triamcinolone acetonide – Inj 40 mg per ml, 1 ml preservative-free

Medicines have been listed in groups according to the therapeutic group classification system used in the Pharmaceutical Schedule. Below is a list of these groups, and the corresponding page numbers. Medicines with indications that may apply to multiple therapeutic groups only appear in one group.

Therapeutic group	Pages
Alimentary Tract and Metabolism	7-8
Blood and Blood Forming Organs	8
Cardiovascular System	8-9
Dermatologicals	9-10
Genito-Urinary System	10-11
Hormone Preparations	11
Infections – Agents for Systemic Use	11-13
Musculoskeletal System	13
Nervous System	13-15
Oncology and Immunosuppressants	15-16
Sensory Organs	16-17

Information provided for each medicine

For each medicine (as defined by chemical name, form, and strength), we have provided:

- the current ex-manufacturer subsidy per unit of measure as of 1 July 2022
- the number of subsidised or partially subsidised units sold in the community in the year ending 30 June 2022
- an estimate of the annual community market value at current subsidies (estimated by multiplying the volume of units subsidised in the year ending 30 June 2022 by the relevant listed unit subsidy as of 1 July 2022)
- comments specifically relating to the tender item and/or its current listing on the Pharmaceutical Schedule.

Hauora Arotahi Māori health areas of focus

Pharmac is continually working to develop and implement advances in Hauora Arotahi to support equitable health outcomes for Māori. Pharmac's Māori health areas of focus voiced by whānau Māori are available [here](#). The draft 2022/23 tender includes treatments for mental health, diabetes, heart health (such as medicines to treat high blood pressure and prevent stroke), respiratory health, and cancer (lung and breast), outlined in tables below.

Chemical Name	Line Item
<i>Cancer – lung and breast</i>	
Anastrozole	Tab 1 mg
Gemcitabine hydrochloride	Inj 1 g
Paclitaxel	Inj 100 mg Inj 300 mg
Tamoxifen citrate	Tab 10 mg Tab 20 mg

Chemical Name	Line Item
<i>Heart health – high blood pressure and stroke</i>	
Ambrisentan	Tab 5 mg Tab 10 mg
Amlodipine	Tab 2.5 mg Tab 5 mg Tab 10 mg
Bisoprolol fumarate	Tab 2.5 mg Tab 5 mg Tab 10 mg
Clonidine	TDDS 2.5 mg, 100 mcg per day TDDS 5 mg, 200 mcg per day TDDS 7.5 mg, 300 mcg per day
Indapamide	Tab 2.5 mg
Losartan	Tab 12.5 mg Tab 25 mg Tab 50 mg

Chemical Name	Line Item
	Tab 100 mg

Chemical Name	Line Item
<i>Mental health</i>	
Amitriptyline	Tab 10 mg Tab 25 mg Tab 50 mg
Diazepam	Tab 2 mg Tab 5 mg
Escitalopram	Tab 10 mg Tab 20 mg
Olanzapine	Tab 2.5 mg Tab 5 mg Tab 10 mg Orodispersible tab 5 mg Orodispersible tab 10 mg
Quetiapine	Tab 25 mg Tab 100 mg Tab 200 mg Tab 300 mg
Risperidone	Tab 0.5 mg Tab 1 mg Tab 2 mg Tab 3 mg Tab 4 mg

Explanation of terms, symbols, and abbreviations

Most terms and abbreviations used are self-explanatory. “Tab” means tablet, “cap” means capsule, “liq” means liquid, “inj” means injection, “suppos” means suppository, “grans” mean granules and “OP” means original pack to be dispensed.

Symbols used in the draft tender list:

Symbol	Explanation
Underlined	Medicine line items where a sole supply or principal supply contract is in force are underlined. The price and subsidy for these medicines are fixed until 30 June 2022 unless otherwise stated in the comments column and a listing of a new brand could only occur after that date.
C	To be tendered for Principal Supply Status (community medicines).
H	To be tendered for Principal Supply Status (hospital medicines).

PCT	Pharmaceuticals Te Whatu Ora - Health New Zealand hospitals may claim a subsidy through Section B of the Pharmaceutical Schedule.
+	Pharmac has been advised of the existence of a patent.
*	There is no fully funded product available for this line item (in relation to community supply).
@	Additional Stock Pharmaceuticals (ASP). The supplier of the successful tender bid would be required to hold additional stock.
#	A rebate currently exists.

Packaging preferences

In the last tender, we began introducing stronger packaging preferences for medicines for pack sizes and packaging types (such as bottles or blister packs). These changes support our focus on environmental sustainability and helping pharmacy workflow. This year we have included such preferences for 33 products. Details are included alongside affected products in Appendix One.

Key dates

- **21 July 2022** – Consultation begins
- **25 August 2022** – Consultation closes
- **September 2022** - Tender Clinical Advisory Committee meets
- **November 2022** – final Invitation to Tender released
- **January 2023** – earliest tender results announced

Providing feedback

Feedback should be provided to the tender analysts via email: tender@pharmac.govt.nz

All feedback received before the closing date will be considered by Pharmac's Board or its delegate before finalising the 2022/23 Invitation to Tender.

Your feedback may be shared

Feedback we receive is subject to the Official Information Act 1982 (OIA). We will consider any request to have information withheld in accordance with our obligations under the OIA. Anyone providing feedback, whether on their own account or on behalf of an organisation, and whether in a personal or professional capacity, should be aware that the content of their feedback and their identity may need to be disclosed in response to an OIA request.

We are not able to treat any part of your feedback as confidential unless you specifically request that we do, and then only to the extent permissible under the OIA and other relevant laws and requirements. If you would like us to withhold any commercially sensitive, confidential proprietary, or personal information included in your submission, please clearly state this in your submission and identify the relevant sections of your submission that you would like it withheld. Pharmac will give due consideration to any such request.

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Alimentary Tract and Metabolism

Chemical Name	Units	Cost	Unit Subsidy	ABA Limit	Comments
Line Item					
Calcium carbonate					
<u>Tab</u>	8,008,658	\$214,312	\$0.0268	C H 5%	Preference for tab 1.25 g - 1.5 g.
Colecalciferol					
<u>Cap/Tab 1.25 mg</u>	3,571,101	\$877,884	\$0.2458	C H 5%	
Docusate Sodium					
<u>Tab 50 mg</u>	884,724	\$20,437	\$0.0231	C H 5%	
<u>Tab 120 mg</u>	1,536,799	\$48,102	\$0.0313	C H 5%	
Fibre supplement					
<u>Powder/granules</u>	73,638,250	\$1,796,773	\$0.0244	C H 5%	Units and unit subsidy shown as per the 500 g presentation currently listed and expressed as 'per g'. Preference for a product containing psyllium husk.
Gliclazide					
<u>Tab 80 mg</u>	21,095,238	\$640,451	\$0.0304	C H 5%	
Glucagon Hydrochloride					
<u>Inj 1 mg syringe kit</u>	21,406	\$684,992	\$32.0000	C H 5%	Preference for a graduated and/or prefilled syringe.
Glucose [Dextrose]					
Solution 15 g				H 5%	
Hyoscine N-butylbromide					
<u>Inj 20 mg, 1 ml</u>	179,634	\$228,135	\$1.2700	C H 5%	
<u>Tab 10 mg</u>	5,761,864	\$365,878	\$0.0635	C H 5%	
Iodine supplement					
<u>Tab 150 mcg elemental</u>	11,892,079	\$605,188	\$0.0509	C H 5%	
Macroglol 3350 with potassium chloride, sodium bicarbonate and sodium chloride					
<u>Powder for oral soln 13.125 g with potassium chloride 46.6 mg, sodium bicarbonate 178.5 mg and sodium chloride 350.7 mg</u>	10,381,124	\$2,318,416	\$0.2233	C H 5%	
Macroglol 3350 with sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid					
Powder for oral soln				H 5%	Not currently listed in the Pharmaceutical Schedule.
Magnesium sulphate					
<u>Inj 2 mmol per ml, 5ml</u>	21,967	\$56,082	\$2.5530	C H 5%	
Mebeverine hydrochloride					
<u>Tab 135 mg</u>	2,754,493	\$281,564	\$0.1022	C H 5%	
Nystatin					
<u>Oral liq 100,000 u per ml</u>	1,728,984	\$126,786	\$0.0733	C H 5%	
Omeprazole					
<u>Cap 10 mg</u>	7,963,375	\$171,690	\$0.0216	C H 5%	Preference for a pack size of 30 or 90 capsules in a bottle pack.
<u>Cap 20 mg</u>	110,835,038	\$2,290,960	\$0.0207	C H 5%	Preference for a pack size of 30 or 90 capsules in a bottle pack.
<u>Cap 40 mg</u>	31,917,260	\$1,103,060	\$0.0346	C H 5%	Preference for a pack size of 30 or 90 capsules in a bottle pack.
Poloxamer					
<u>Oral drops 10%</u>	275,430	\$36,541	\$0.1327	C H 5%	
Prednisolone					
Rectal Foam 10 - 20%	1,204	\$6,373	\$5.2929	C H 5%	Pharmac reserves the right to award a tender to one steroidal rectal product for the whole market.
Pyridoxine hydrochloride					
<u>Tab 25 mg</u>	1,157,966	\$34,739	\$0.0300	C H 5%	

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Alimentary Tract and Metabolism

Chemical Name Line Item	Units	Cost	Unit Subsidy	ABA Limit	Comments
Rifaximin <u>Tab 200 mg - 550 mg</u>	177,640	\$1,982,588	\$11.1607	C H 5%	Tab 550 mg is currently listed on the Pharmaceutical Schedule. Units shown are for tab 550 mg.
Triamcinolone acetonide <u>0.1% in Dental Paste USP</u>	127,930	\$136,373	\$1.0660	C H 5%	
Ursodeoxycholic acid <u>Cap 250 mg - 300 mg</u>	1,096,709	\$361,366	\$0.3295	C H 5%	Cap 250 mg is currently listed on the Pharmaceutical Schedule. Units shown are for cap 250 mg.

Blood and Blood Forming Organs

Chemical Name Line Item	Units	Cost	Unit Subsidy	ABA Limit	Comments
Aspirin <u>Tab 100 mg EC</u>	88,360,404	\$963,932	\$0.0109	C H 5%	
Glucose [Dextrose] <u>Inj 50%, 10 ml - 20 ml</u>	12,511	\$76,692	\$6.1300	C H 5%	Inj 50%, 10 ml is currently listed on the Pharmaceutical Schedule. Units and subsidy are shown per 10 ml ampoule.
<u>Inj 50%, 90 ml - 100 ml</u>	476	\$7,140	\$15.0000	C H 5%	Inj 50%, 90 ml is currently listed on the Pharmaceutical Schedule. Units and subsidy are shown per 90 ml ampoule.

Cardiovascular System

Chemical Name Line Item	Units	Cost	Unit Subsidy	ABA Limit	Comments
Ambrisentan <u>Tab 10 mg</u>	11,650	\$601,917	\$51.6667	C H 5%	Longer transition period may apply to this product.
<u>Tab 5 mg</u>	4,056	\$209,560	\$51.6667	C H 5%	Longer transition period may apply to this product.
Amlodipine <u>Tab 2.5 mg</u>	14,097,368	\$169,168	\$0.0120	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.
<u>Tab 5 mg</u>	25,695,696	\$274,173	\$0.0107	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.
<u>Tab 10 mg</u>	13,591,221	\$179,676	\$0.0132	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.
Bendroflumethiazide [Bendrofluazide] <u>Tab 2.5 mg</u>	17,533,816	\$701,353	\$0.0400	C H 5%	
<u>Tab 5 mg</u>	2,645,959	\$182,836	\$0.0691	C H 5%	
Bisoprolol Fumarate <u>Tab 2.5 mg</u>	13,286,711	\$271,580	\$0.0204	C H 5%	Preference for a scored tablet, and for a pack size of 30 or 90 tablets in a bottle pack.
<u>Tab 5 mg</u>	7,057,743	\$199,946	\$0.0283	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.
<u>Tab 10 mg</u>	2,412,029	\$97,012	\$0.0402	C H 5%	Preference for a pack ize of 30 or 90 tablets in a bottle pack.
Clonidine <u>TDDS 2.5 mg, 100 mcg per day</u>	66,540	\$172,006	\$2.5850	C H 5%	
<u>TDDS 5 mg, 200 mcg per day</u>	29,123	\$95,960	\$3.2950	C H 5%	
<u>TDDS 7.5 mg, 300 mcg per day</u>	18,479	\$78,212	\$4.2325	C H 5%	
Ephedrine <u>Inj 30 mg per ml, 1ml</u>				H 5%	
Ezetimibe <u>Tab 10 mg</u>	8,228,171	\$534,831	\$0.0650	C H 5%	
<u>sole supply</u>					

#=-rebate *=-part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Cardiovascular System

Chemical Name Line Item	Units	Cost	Unit Subsidy	ABA Limit	Comments
Flecainide Acetate					
Cap long-acting 100 mg	1,109,011	\$486,856	\$0.4390	C H 5%	Longer transition timeframes may apply.
Cap long-acting 200 mg	1,112,332	\$754,655	\$0.6784	C H 5%	Longer transition timeframes may apply.
Inj 10 mg per ml, 15 ml	51	\$1,020	\$20.0000	C H 5%	
Tab 50 mg	419,485	\$139,479	\$0.3325	C H 5%	Longer transition timeframes may apply.
Glyceryl trinitrate					
Inj 1 mg per ml, 10 ml				H 5%	
Indapamide					
Tab 2.5 mg	2,035,333	\$236,323	\$0.1161	C H 5%	
Isosorbide mononitrate					
Tab 20 mg	580,607	\$113,509	\$0.1955	C H 5%	
Tab long-acting 40 mg	636,991	\$174,109	\$0.2733	C H 5%	
Tab long-acting 60 mg	6,410,771	\$658,899	\$0.1028	C H 5%	
Losartan					
Tab 12.5 mg	5,909,927	\$109,747	\$0.0186	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.
Tab 25 mg	9,210,090	\$201,701	\$0.0219	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.
Tab 50 mg	12,457,774	\$333,744	\$0.0268	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.
Tab 100 mg	7,638,854	\$318,311	\$0.0417	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.
Metaraminol tartrate					
Inj 0.5 mg per ml, 10 ml				H 5%	
Inj 0.5 mg per ml, 20 ml				H 5%	
Inj 0.5 mg per ml, 5 ml					
Inj 1 mg per ml, 1 ml				H 5%	
Inj 1 mg per ml, 10 ml				H 5%	
Inj 10 mg per ml, 1 ml				H 5%	
Pravastatin					
Tab 20 mg	3,822,866	\$288,091	\$0.0754	C H 5%	
Tab 40 mg	2,073,130	\$267,289	\$0.1289	C H 5%	
Rosuvastatin					
Tab 5 mg	210,363	\$11,921	\$0.0567	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.
Tab 10 mg	371,573	\$29,974	\$0.0807	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.
Tab 20 mg	420,277	\$54,916	\$0.1307	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.
Tab 40 mg	337,648	\$59,426	\$0.1760	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.
Simvastatin					
Tab 10 mg	3,075,595	\$42,043	\$0.0137	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.
Tab 20 mg	13,253,968	\$299,010	\$0.0226	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.
Tab 40 mg	11,383,998	\$452,855	\$0.0398	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.
Tab 80 mg	772,532	\$61,115	\$0.0791	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.

Dermatologicals

Chemical Name Line Item	Units	Cost	Unit Subsidy	ABA Limit	Comments
Acitretin					
Cap 10 mg	520,425	\$154,915	\$0.2977	C H 5%	Preference for a blister pack.

sole supply

#=rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Dermatologicals

Chemical Name Line Item	Units	Cost	Unit Subsidy	ABA Limit	Comments
Acitretin					
Cap 25 mg	104,703	\$72,175	\$0.6893	C H 5%	Preference for a blister pack.
Amorolfine					
Nail soln 5%	148,135	\$442,331	\$2.9860	C H 5%	
Betamethasone Dipropionate					
Crn 0.05% (pack size greater than 30 g)	386,770	\$278,474	\$0.7200	C H 5%	
Oint 0.05% (pack size greater than 30 g)	421,840	\$303,725	\$0.7200	C H 5%	
Emulsifying ointment					
Oint BP (pack size of 200 g or less)				H 5%	
Oint BP (pack size greater than 200 g)	32,574,394	\$221,506	\$0.0068	C H 5%	
Hydrocortisone with wool fat and mineral oil					
Lotn 1% with wool fat hydrous 3% and mineral oil	10,570,725	\$446,930	\$0.0423	C H 5%	Preference for a pack size of 300 g or less.
Ketoconazole					
Shampoo 2%	6,451,100	\$208,371	\$0.0323	C H 5%	
Methylprednisolone aceponate					
Crn 0.1%	549,540	\$163,395	\$0.2973	C H 5%	
Oint 0.1%	362,580	\$107,806	\$0.2973	C H 5%	
Miconazole nitrate					
Crn 2% (15 g - 20 g pack)	2,796,060	\$150,987	\$0.0540	C H 5%	
Paraffin					
White soft (pack size 2000 g or more)	2,071,299	\$16,562	\$0.0080	C 5%	Only funded in combination.
White soft (pack size 500 g or less)	128,146	\$1,421	\$0.0111	C H 5%	
Permethrin					
Lotion 5%	1,209,090	\$160,809	\$0.1330	C H 5%	
Pimecrolimus					
Crn 1%	52,530	\$99,807	\$1.9000	C H 5%	
Pine tar with triethanolamine lauryl sulphate and fluorescein					
Soln 2.3% with triethanolamine lauryl sulphate and fluorescein sodium	21,626,777	\$192,046	\$0.0089	C H 5%	
Povidone Iodine					
Oint 10%	941,901	\$107,188	\$0.1138	C H 5%	
Tacrolimus					
Oint 0.1%	62,190	\$68,409	\$1.1000	C H 5%	
Triamcinolone acetonide					
Crn 0.02%	3,294,400	\$207,547	\$0.0630	C H 5%	
Oint 0.02%	1,887,600	\$119,863	\$0.0635	C H 5%	

Genito-Urinary System

Chemical Name Line Item	Units	Cost	Unit Subsidy	ABA Limit	Comments
Cyproterone acetate with ethinyloestradiol					
Tab 2 mg with ethinyloestradiol 35 mcg				C H 5%	Not currently listed in the Pharmaceutical Schedule. Pharmac would consider bids for products not containing inert tablets. Pharmac reserves the right to award a single tender for the entire cyproterone with ethinyloestradiol market.
Tab 2 mg with ethinyloestradiol 35 mcg and 7 inert tablets	9,479,568	\$280,974	\$0.0296	C H 5%	Pharmac reserves the right to award a single tender for the entire cyproterone with ethinyloestradiol market.
Finasteride					
Tab 5 mg	5,811,630	\$279,539	\$0.0481	C H 5%	Preference for a blister pack.

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Genito-Urinary System

Chemical Name Line Item	Units	Cost	Unit Subsidy	ABA Limit	Comments
Levonorgestrel					
<u>Subdermal implant</u>	12,179	\$1,302,179	\$106.9200	C H 5%	Longer transition periods may apply to this product. Training should be provided to clinicians if awarded. Refer to Schedule 5 for additional Special Terms.
Miconazole nitrate					
<u>Vaginal crm 2% with applicator</u>	452,760	\$77,988	\$0.1723	C H 5%	Single use applicators preferred.
Nystatin					
<u>Vaginal crm 100,000 u per 5 g with applicator(s)</u>	144,750	\$7,720	\$0.0533	C H 5%	Units and unit subsidy expressed as 'per g'.
Oestriol					
<u>Crm 1 mg per g with applicator(s)</u>	3,622,485	\$1,598,711	\$0.4413	C H 5%	Applicator(s) should be multiple use and a measured dose.
<u>Pessaries 500 mcg</u>	417,780	\$191,063	\$0.4573	C H 5%	
Sodium Citro-Tartrate					
<u>Grans effervescent 4 g sachets</u>	2,335,205	\$185,158	\$0.0793	C H 5%	

Hormone Preparations - Systemic Excluding Contraceptive Hormones

Chemical Name Line Item	Units	Cost	Unit Subsidy	ABA Limit	Comments
Desmopressin					
<u>Nasal spray 10 mcg per dose</u>	88,284	\$411,256	\$4.6583	C H 5%	
Goserelin					
Implant 10.8 mg, syringe	26,907	\$3,292,610	\$122.3700	C H 5%	Refer to Schedule 5 for additional Special Terms.
Implant 3.6 mg, syringe	11,410	\$749,435	\$65.6800	C H 5%	Refer to Schedule 5 for additional Special Terms.
Metyrapone					
<u>Cap 250 mg</u>	29,585	\$330,169	\$11.1600	C 5%	
Oestriol					
<u>Tab 2 mg</u>	166,032	\$38,735	\$0.2333	C H 5%	Preference for tablets to be scored.
Triamcinolone acetonide					
<u>Inj 10 mg per ml, 1 ml</u>	4,352	\$18,104	\$4.1600	C H 5%	Pharmac reserves the right to list a preservative free product in addition to this product for the ophthalmic market.
<u>Inj 40 mg per ml, 1 ml</u>	71,614	\$731,895	\$10.2200	C H 5%	Pharmac reserves the right to list a preservative free product in addition to this product for the ophthalmic market.

Infections

Chemical Name Line Item	Units	Cost	Unit Subsidy	ABA Limit	Comments
Amoxicillin					
<u>Grans for oral liq 125 mg per 5 ml</u>	5,626,189	\$78,767	\$0.0140	C H 5%	Preference for products which include a measuring device.
<u>Grans for oral liq 250 mg per 5 ml</u>	32,477,430	\$561,860	\$0.0173	C H 5%	Preference for products which include a measuring device.
Amoxicillin clavulanate					
Tab amoxicillin 500 mg with potassium clavulanate 125 mg	10,325,281	\$918,950	\$0.0890	@ C H 5%	
Azithromycin					
Tab 250 mg	60,420	\$16,495	\$0.2730	C H 5%	
Benzylopenicillin sodium [Penicillin G]					
<u>Inj 600 mg</u>	5,526	\$6,128	\$1.1090	C H 5%	
Cefazolin sodium					
Inj 2 g				C H 5%	Not currently listed on the Pharmaceutical Schedule.

sole supply

#=rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Infections

Chemical Name	Units	Cost	Unit Subsidy	ABA Limit	Comments
Line Item					
Cefazolin sodium					
<u>Inj 500 mg</u>	340	\$231	\$0.6780	C H 5%	
<u>Inj 1 g</u>	20,197	\$14,098	\$0.6980	C H 5%	
Cefotaxime					
<u>Inj 1 g</u>				H 5%	
Ceftazidime					
<u>Inj 1 g</u>				H 5%	
Cefuroxime sodium					
<u>Inj 750 mg</u>				H 5%	
<u>Inj 1.5 g</u>				H 5%	
Ciprofloxacin					
<u>Tab 250 mg</u>	138,119	\$11,938	\$0.0864	C H 5%	Preference for a scored, dispersible tablet.
<u>Tab 500 mg</u>	769,202	\$93,404	\$0.1214	C H 5%	Preference for a scored, dispersible tablet.
<u>Tab 750 mg</u>	32,175	\$6,837	\$0.2125	C H 5%	Preference for a scored, dispersible tablet.
Clarithromycin					
<u>Inj 500 mg</u>				H 5%	
Colistin Sulphomethate					
<u>Inj 150 mg</u>	5,874	\$381,810	\$65.0000	C H 5%	
Darunavir					
<u>Tab 400 mg</u>	81,856	\$180,083	\$2.2000	C H 5%	Preference for a dispersible tablet.
<u>Tab 600 mg</u>	26,184	\$85,818	\$3.2775	C H 5%	Preference for a dispersible tablet.
Flucloxacillin sodium					
<u>Inj 1 g</u>	6,161	\$7,024	\$1.1400	C H 5%	
Fluconazole					
<u>Cap 50 mg</u>	181,884	\$17,863	\$0.0982	C H 5%	
<u>Cap 150 mg</u>	134,034	\$87,122	\$0.6500	C H 5%	
<u>Cap 200 mg</u>	80,333	\$36,982	\$0.4604	C H 5%	
Fosfomycin (current access)					
<u>Powder</u>				H 5%	
Fosfomycin (widened access)					
<u>Powder</u>				C H 5%	Not currently listed in Section B. Special Authority criteria may apply. No proposed changes to Section H restrictions.
Ganciclovir					
<u>Inj 500 mg vial</u>				H 5%	
Lamivudine					
<u>Tab 100 mg</u>	78,239	\$19,420	\$0.2482	C H 5%	
<u>Tab 150 mg</u>	148,170	\$208,672	\$1.4083	C H 5%	
Meropenem					
<u>Inj 500 mg</u>				H 5%	
<u>Inj 1 g</u>				H 5%	
Metronidazole					
<u>Inj 5 mg per ml, 100 ml</u>				H 5%	Preference for a bag presentation with space to add another antibiotic.
<u>Tab 200 mg</u>	362,003	\$48,002	\$0.1326	C H 5%	Preference for a scored, dispersible tablet.
<u>Tab 400 mg</u>	2,112,363	\$526,084	\$0.2491	C H 5%	
Moxifloxacin					
<u>Tab 400 mg</u>	17,981	\$151,040	\$8.4000	C H 5%	
Rifampicin					
<u>Cap 150 mg</u>	67,362	\$39,434	\$0.5854	C H 5%	
<u>Cap 300 mg</u>	177,112	\$216,183	\$1.2206	C H 5%	
<u>Inj 600 mg</u>				H 5%	
<u>Oral liq 100 mg per 5 ml</u>	74,501	\$15,645	\$0.2100	C H 5%	

sole supply

#=rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Infections

Chemical Name	Units	Cost	Unit Subsidy	ABA Limit	Comments
Line Item					
Roxithromycin					
Tab 150 mg	1,312,868	\$217,411	\$0.1656 @	C H 5%	Additional Stock Pharmaceutical
Tab 300 mg	635,051	\$207,408	\$0.3266 @	C H 5%	Additional Stock Pharmaceutical
Terbinafine					
Tab 250 mg	2,026,389	\$196,600	\$0.0970	C H 5%	
Tobramycin					
Solution for inhalation 60 mg per ml, 5 ml	15,015	\$105,909	\$7.0536	C H 5%	
Vancomycin hydrochloride					
Inj 500 mg	7,653	\$17,985	\$2.3500	C H 5%	

Musculoskeletal System

Chemical Name	Units	Cost	Unit Subsidy	ABA Limit	Comments
Line Item					
Allopurinol					
Tab 100 mg	28,298,623	\$649,170	\$0.0229	C H 5%	Preference for a scored tablet.
Tab 300 mg	21,118,812	\$1,206,729	\$0.0571	C H 5%	Preference for a scored tablet.
Atracurium Besylate					
Inj 10 mg per ml, 2.5 ml				H 5%	
Inj 10 mg per ml, 5 ml				H 5%	
Capsaicin					
Crm 0.025%	2,535,075	\$549,266	\$0.2167	C H 5%	
Febuxostat					
Tab 120 mg	169,333	\$120,955	\$0.7143	C H 5%	
Tab 80 mg	676,395	\$483,142	\$0.7143	C H 5%	
Leflunomide					
Tab 10 mg	616,953	\$123,391	\$0.2000	C H 5%	Preference for a scored tablet.
Tab 20 mg	798,875	\$159,775	\$0.2000	C H 5%	
Suxamethonium chloride					
Inj 50 mg per ml, 2 ml				H 5%	

Nervous System

Chemical Name	Units	Cost	Unit Subsidy	ABA Limit	Comments
Line Item					
Alfentanil					
Inj 0.5 mg per ml, 2 ml ampoule				H 5%	
Amitriptyline					
Tab 10 mg	25,181,446	\$627,018	\$0.0249	C H 5%	Preference for a scored and/or dispersible tablet.
Tab 25 mg	8,159,364	\$123,206	\$0.0151	C H 5%	
Tab 50 mg	3,073,595	\$77,147	\$0.0251	C H 5%	
Aspirin					
Tab dispersible or soluble 300 mg	781,454	\$35,165	\$0.0450	C H 5%	
Benzatropine Mesylate					
Inj 1 mg per ml, 2 ml ampoule	1,002	\$19,038	\$19.0000	C H 5%	
Betahistine dihydrochloride					
Tab 16 mg	4,130,294	\$190,820	\$0.0462	C H 5%	
Bupivacaine hydrochloride					
Inj 2.5 mg per ml, 20 ml ampoule				H 5%	
Inj 2.5 mg per ml, 100 ml bag				H 5%	
Inj 5 mg per ml, 4 ml				H 5%	
Bupropion hydrochloride					
Tab modified-release 150 mg	3,184,267	\$1,167,575	\$0.3667	C H 5%	

sole supply

#=rebate * =part charge @ =ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Nervous System

Chemical Name	Units	Cost	Unit Subsidy	ABA Limit	Comments
Line Item					
Capsaicin (current access)					
<u>Crm 0.075%</u>	505,329	\$134,215	\$0.2656	C H 5%	Current restrictions may apply. Pharmac would only award a tender for either current or widened access. Widened access would be a listing on the Schedule without restrictions.
Capsaicin (widened access)					
Crm 0.075%				C H 5%	Pharmac would only award a tender for either current or widened access. Widened access would be a listing on the Schedule without restrictions.
Dexmedetomidine hydrochloride					
Inj 100 mcg per ml, 2 ml vial				H 5%	
Diazepam					
<u>Tab 2 mg</u>	2,924,149	\$357,156	\$0.1221	C H 5%	Preference for a scored tablet.
<u>Tab 5 mg</u>	4,394,023	\$646,800	\$0.1472	C H 5%	
Donepezil hydrochloride					
<u>Tab 5 mg</u>	1,347,891	\$64,995	\$0.0482	C H 5%	
<u>Tab 10 mg</u>	1,184,480	\$87,391	\$0.0738	C H 5%	
Escitalopram					
<u>Tab 10 mg</u>	15,105,621	\$577,186	\$0.0382	C H 5%	Preference for a scored tablet.
<u>Tab 20 mg</u>	5,208,199	\$357,126	\$0.0686	C H 5%	
Granisetron					
Inj 1 mg per ml				H 5%	
Levodopa with Carbidopa					
<u>Tab 100 mg with carbidopa 25 mg</u>	9,913,017	\$2,092,638	\$0.2111	C H 5%	Longer transition periods may apply to this product.
<u>Tab 250 mg with carbidopa 25 mg</u>	347,736	\$133,496	\$0.3839	C H 5%	Longer transition periods may apply to this product.
<u>Tab long-acting 200 mg with carbidopa 50 mg</u>	1,836,240	\$801,519	\$0.4365	C H 5%	Longer transition periods may apply to this product. Pharmacokinetic data required.
Metoclopramide hydrochloride					
<u>Tab 10 mg</u>	5,736,378	\$74,573	\$0.0130	C H 5%	
Morphine					
Inj 1 mg per ml, 10 ml syringe				H 5%	Morphine sulphate inj 1 mg per ml, 10 ml syringe is currently listed in Section H of the Pharmaceutical Schedule.
Inj 1 mg per ml, 100 ml bag				H 5%	Morphine sulphate inj 1 mg per ml, 100 ml bag is currently listed in Section H of the Pharmaceutical Schedule.
Inj 1 mg per ml, 50 ml syringe				H 5%	Morphine sulphate inj 1 mg per ml, 50 ml syringe is currently listed in Section H of the Pharmaceutical Schedule.
<u>Tab immediate-release 10 mg</u>	3,759,493	\$1,052,658	\$0.2800	C H 5%	Preference for blister packs. Units and subsidy shown are for morphine sulphate tab immediate-release 10 mg.
<u>Tab immediate-release 20 mg</u>	632,388	\$349,078	\$0.5520	C H 5%	Preference for blister packs. Units and subsidy shown are for morphine sulphate tab immediate-release 20 mg.
Naltrexone hydrochloride					
<u>Tab 50 mg</u>	264,115	\$1,173,812	\$4.4443	C H 5%	
Olanzapine					
<u>Orodispersible tab 5 mg</u>	392,548	\$25,374	\$0.0646	C H 5%	
<u>Orodispersible tab 10 mg</u>	537,702	\$45,705	\$0.0850	C H 5%	
<u>Tab 2.5 mg</u>	2,129,083	\$102,643	\$0.0482	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.
<u>Tab 5 mg</u>	2,691,178	\$151,863	\$0.0564	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.

sole supply

#=rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Nervous System

Chemical Name	Units	Cost	Unit Subsidy	ABA Limit	Comments
Line Item					
Olanzapine					
Tab 10 mg	2,961,970	\$212,640	\$0.0718	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.
Ondansetron					
Tab disp 4 mg	2,986,569	\$226,979	\$0.0760	C H 5%	
Tab disp 8 mg	1,234,570	\$139,506	\$0.1130	C H 5%	
Paracetamol					
Suppos 125 mg	108,084	\$38,802	\$0.3590	C H 5%	
Inj 10 mg per ml, 100 ml				H 5%	
Suppos 250 mg	60,840	\$25,431	\$0.4180	C H 5%	
Suppos 500 mg	121,489	\$30,129	\$0.2480	C H 5%	
Prochlorperazine					
Tab 5 mg	3,449,692	\$110,390	\$0.0320	C H 5%	
Quetiapine					
Tab 100 mg	4,138,527	\$232,668	\$0.0562	C H 5%	Preference for a pack size of 30 or 90 tablets in a blister pack.
Tab 200 mg	1,192,165	\$117,893	\$0.0989	C H 5%	Preference for a pack size of 30 or 90 tablets in a blister pack.
Tab 25 mg	28,110,192	\$671,552	\$0.0239	C H 5%	Preference for a scored tablet, and for a pack size of 30 or 90 tablets in a bottle pack.
Tab 300 mg	486,185	\$69,471	\$0.1429	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.
Remifentanil hydrochloride					
Inj 1 mg				H 5%	
Inj 2 mg				H 5%	
Risperidone					
Oral liquid 1 mg per ml	436,001	\$129,348	\$0.2967	C H 5%	
Tab 0.5 mg	3,374,198	\$104,600	\$0.0310	C H 5%	Preference for a pack size of 60 or 180 tablets in a bottle pack.
Tab 1 mg	2,167,617	\$74,414	\$0.0343	C H 5%	Preference for a pack size of 60 or 180 tablets in a bottle pack.
Tab 2 mg	1,007,412	\$38,453	\$0.0382	C H 5%	Preference for a pack size of 60 or 180 tablets in a bottle pack.
Tab 3 mg	426,586	\$17,776	\$0.0417	C H 5%	Preference for a pack size of 60 or 180 tablets in a bottle pack.
Tab 4 mg	187,866	\$10,708	\$0.0570	C H 5%	Preference for a pack size of 60 or 180 tablets in a bottle pack.
Rizatriptan					
Tab orodispersible 10 mg	2,235,118	\$271,947	\$0.1217	C H 5%	
Ropivacaine hydrochloride					
Inj 2 mg per ml, 10 ml ampoule				H 5%	
Inj 2 mg per ml, 20 ml				H 5%	
Inj 2 mg per ml, 100 ml				H 5%	
Inj 2 mg per ml, 200 ml				H 5%	
Inj 7.5 mg per ml, 10 ml				H 5%	
Inj 7.5 mg per ml, 20 ml				H 5%	
Inj 10 mg per ml, 10 ml				H 5%	
Inj 10 mg per ml, 20 ml				H 5%	
Temazepam					
Tab 10 mg	2,621,249	\$139,450	\$0.0532	C H 5%	Preference for a scored tablet.
Teriflunomide					
Tab 14 mg	14,196	\$334,569	\$23.5679	C H 5%	
Tramadol hydrochloride					
Cap 50 mg	31,652,770	\$886,278	\$0.0280	C H 5%	
Inj 50 mg per ml, 1 ml ampoule				H 5%	

sole supply

#=rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Nervous System

Chemical Name Line Item	Units	Cost	Unit Subsidy	ABA Limit	Comments
Tramadol hydrochloride					
Inj 50 mg per ml, 2 ml ampoule				H 5%	
<u>Tab sustained-release 100 mg</u>	5,186,631	\$394,184	\$0.0760	C H 5%	
<u>Tab sustained-release 150 mg</u>	480,172	\$50,418	\$0.1050	C H 5%	
<u>Tab sustained-release 200 mg</u>	355,869	\$48,932	\$0.1375	C H 5%	

Oncology Agents and Immunosuppressants

Chemical Name Line Item	Units	Cost	Unit Subsidy	ABA Limit	Comments
Anastrozole					
Tab 1 mg	668,016	\$101,318	\$0.1517	C H 5%	
Bicalutamide					
<u>Tab 50 mg</u>	695,680	\$104,602	\$0.1504	C H 5%	
Bleomycin Sulphate					
Inj 15,000 iu vial				PCT H 5%	
Cisplatin					
Inj 1 mg per ml, 50 ml				PCT H 5%	
Gemcitabine hydrochloride					
<u>Inj 1 g</u>				PCT H 5%	
Hydroxyurea					
Cap 500 mg	1,353,460	\$322,394	\$0.2382	PCT C H 5%	
Imatinib mesilate					
Cap 400 mg	102,421	\$289,476	\$2.8263	C H 5%	Pharmac reserves the right to award a tender for all indications. Additional implementation support may be required to support a brand change. Usage figures are for non-GIST market only.
Cap 100 mg	155,738	\$151,144	\$0.9705	C H 5%	Pharmac reserves the right to award a tender for all indications. Additional implementation support may be required to support a brand change. Usage figures are for non-GIST market only.
Melphalan					
Inj 50 mg vial				PCT H 1%	
Methotrexate					
<u>Inj 100 mg per ml, 50 ml</u>		\$65,805	\$79.9900	PCT C H 5%	Preference for products where stability data >48 hours post-compounding.
Paclitaxel					
Inj 100 mg				PCT H 5%	Preference for products where stability data >48 hours post-compounding.
Inj 300 mg				PCT H 5%	Preference for products where stability data >48 hours post-compounding.
Tamoxifen citrate					
<u>Tab 10 mg</u>	44,665	\$11,166	\$0.2500	C H 5%	
<u>Tab 20 mg</u>	1,766,310	\$195,760	\$0.1108	C H 5%	

Sensory Organs

Chemical Name Line Item	Units	Cost	Unit Subsidy	ABA Limit	Comments
Atropine sulphate					
<u>Eye drops 1%</u>	116,010	\$134,262	\$1.1573	C H 5%	
Latanoprost with timolol					
<u>Eye drops 0.005% with timolol 0.5%</u>	46,630	\$23,222	\$0.4980	C H 5%	

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Sensory Organs

Chemical Name	Units	Cost	Unit Subsidy	ABA Limit	Comments
Line Item					
Timolol					
Eye drops 0.5%, gel forming	55,038	\$83,217	\$1.5120	C H 5%	For products containing BAK, Pharmac reserves its right to list a BAK or preservative free product for a restricted market. Units and unit subsidy shown are per ml
Timolol maleate					
<u>Eye drops 0.25%</u>	212,790	\$77,030	\$0.3620	C H 5%	For products containing BAK, Pharmac reserves the right to list a BAK or preservative free product for a restricted market. Please note that this line item is for non gel-forming drops.
<u>Eye drops 0.5%</u>	145,920	\$59,535	\$0.4080	C H 5%	For products containing BAK, Pharmac reserves the right to list a BAK or preservative free product for a restricted market. Please note that this line item is for non gel-forming drops.
Triamcinolone acetonide					
Inj 10 mg per ml, 1 ml preservative-free				C H 5%	Not currently listed in the Pharmaceutical Schedule. Restrictions may apply.
Inj 40 mg per ml, 1 ml preservative-free				C H 5%	Not currently listed in the Pharmaceutical Schedule. Restrictions may apply.